About this item:

16 Views | 1 Download

Author Notes:

Corresponding Author: Malu Tansey, Department of Physiology Emory University School of Medicine 615 Michael Street Atlanta, Georgia 30322.

Subjects:

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Neurosciences
  • Pharmacology & Pharmacy
  • Neurosciences & Neurology
  • microglia
  • Parkinson's disease
  • neuroinflammation
  • neurodegeneration
  • peripheral immune cell
  • BBB
  • BLOOD-BRAIN-BARRIER
  • NONSTEROIDAL ANTIINFLAMMATORY DRUGS
  • CENTRAL-NERVOUS-SYSTEM
  • SYNUCLEIN ACTIVATES MICROGLIA
  • NIGRAL DOPAMINERGIC-NEURONS
  • ALPHA-SYNUCLEIN
  • OXIDATIVE STRESS
  • NEURODEGENERATIVE DISEASES
  • ALZHEIMER-DISEASE
  • CELL-DEATH

Neuroinflammation in Parkinson's Disease

Tools:

Journal Title:

Journal of Neuroimmune Pharmacology

Volume:

Volume 4, Number 4

Publisher:

, Pages 419-429

Type of Work:

Article | Post-print: After Peer Review

Abstract:

During the last two decades, a wealth of animal and human studies has implicated inflammation-derived oxidative stress and cytokine-dependent neurotoxicity in the progressive degeneration of the dopaminergic nigrostriatal pathway, the hallmark of Parkinson's disease (PD). In this review, we discuss the various hypotheses regarding the role of microglia and other immune cells in PD pathogenesis and progression, the inflammatory mechanisms implicated in disease progression from pre-clinical and clinical studies, the recent evidence that systemic inflammation can trigger microglia activation in PD-relevant central nervous system regions, the synergism between gene products linked to parkinsonian phenotypes (α-synuclein, parkin, Nurr1, and regulator of G-protein signaling-10) and neuroinflammation in promoting neurodegeneration of the nigrostriatal pathway, and the latest update on meta-analysis of epidemiological studies on the risk-lowering effects of anti-inflammatory drug regimens.

Copyright information:

© 2009 Springer Science+Business Media, LLC.

Export to EndNote